A-shares experienced a downturn on July 30, with the technology sector suffering another heavy blow, while healthcare stocks at low levels showed some localized activity, demonstrating resilience. The medical sector had a mixed performance, with medical device leaders 迈瑞医疗 and 联影医疗 closing up 4.35% and 2.21%, respectively. Consumer medical segments like medical aesthetics and ophthalmology rose broadly, with 爱美客 gaining 3.3% and 爱尔眼科 rising 2.37%. Overnight, the Federal Reserve adopted a hawkish tone, causing CXO leaders to collectively turn lower, with 药明康德 falling 0.81% and 凯莱英 dropping nearly 6%. The largest medical ETF in the market, 医疗ETF华宝 (512170), initially traded against the market trend in the red at the open, recovered from afternoon lows, and ultimately closed down 0.31%, outperforming the broader market. It had a full-day turnover of 5.23 billion yuan and an amplitude of 2.45%.
The pharmaceutical sector was also divided, with traditional Chinese medicine (TCM) stocks, which have consumer attributes, rising against the market. 东阿阿胶 led the gains, up 2.68%, while 云南白药, 片仔癀, 同仁堂, and others rose by more than 1%. Interest-rate-sensitive innovative drug assets saw broad adjustments, with 泽璟制药-U leading the decline, dropping 10.57%, 荣昌生物 falling 5.78%, and 百济神州 down 3.38%. The only ETF in the market tracking the pharmaceutical index, 药ETF华宝 (562050), rose and fell in early trading, then rebounded from a 1.65% low in the afternoon, eventually closing down 0.72% with an amplitude of 2.57%.
From a daily K-line perspective, 药ETF华宝 (562050) successfully held the 200-day moving average today, while 医疗ETF华宝 (512170) formed a doji candlestick, losing the 200-day moving average after briefly reclaiming it. Looking ahead, if these two ETFs can firmly hold the 200-day moving average, the current recovery may be poised for further progress. Currently, the technology sector is still in a volatile phase, creating a strong demand for capital to rotate from high to low positions, making low-level healthcare stocks attractive in terms of valuation. 药ETF华宝 (562050) and 医疗ETF华宝 (512170) fund manager 张放 previously noted that after a prolonged and significant decline, the overall valuation of the healthcare sector is at historically low levels, offering high investment value. As such, it is more likely to attract capital attention during market style rebalancing.
Policy support is also increasing. Recently, the State Council released the "15th Five-Year Plan for Expanding Consumption." Analysis suggests that the plan establishes consumption as a core long-term strategy rather than a short-term tool for stable growth. In line with the continuous increase in the proportion of service-oriented consumption, the medical service sector and the consumer-oriented TCM sector are worth watching. To capture opportunities in the healthcare recovery, investors can focus on two key investment tools: 医疗ETF华宝 (512170): the largest medical and healthcare ETF in the market by scale, focusing on medical devices (including brain-computer interfaces) and medical services (CXO, medical aesthetics, private hospitals), also embracing AI medical concepts. Off-exchange linked fund: 012323. 药ETF华宝 (562050): the only ETF in the market tracking the pharmaceutical index, with a unique "72% innovative drugs + 22% TCM" ratio, combining high growth of innovative drugs and high dividends of TCM. Off-exchange linked fund: 024986. Data sourced from the Shanghai and Shenzhen stock exchanges, CSI Index Company, etc., as of June 30, 2026. 医疗ETF华宝 has a scale of 25.623 billion yuan, ranking first among all medical and healthcare ETFs in the market. Note: The ETFs mentioned in the article do not charge sales service fees. Fund fee rates are detailed in each fund's legal documents. Risk warning: The index constituent stocks mentioned are for display purposes only; individual stock descriptions do not constitute any form of investment advice and do not represent the holdings or trading intentions of any fund under the management company. The composition of the underlying index constituent stocks is adjusted according to the index compilation rules. Historical annual returns/volatility for the CSI Medical Index from 2021-2025: -14.71%/34.42%, -25.10%/29.45%, -24.25%/18.63%, -17.16%/36.02%, 3.08%/19.73%. Historical annual returns/volatility for the CSI Pharmaceutical Index from 2021-2025: -9.10%/23.43%, -21.09%/25.92%, -3.70%/18.25%, -6.53%/29.46%, 9.38%/16.12%. The composition of index constituent stocks is adjusted according to the index compilation rules. Past performance does not predict future results. The fund manager assesses the risk level of the Medical ETF linked fund as R4 (medium-high risk), suitable for aggressive (C4) and above investors. The risk level of the Medical ETF and Pharmaceutical ETF is R3 (medium risk), suitable for balanced (C3) and above investors. Any information appearing in this article (including but not limited to individual stocks, comments, forecasts, charts, indicators, theories, any form of expression, etc.) is for reference only. Investors must be responsible for their own investment decisions. Additionally, any views, analyses, and forecasts in this article do not constitute investment advice to readers and shall not be held liable for any direct or indirect losses arising from the use of this content. Fund investment carries risks. A fund's past performance does not represent its future performance. The performance of other funds managed by the fund manager does not constitute a guarantee of the fund's performance. Fund investment requires caution. A MACD golden cross signal has formed, and these stocks are performing well!
Comments